"Anti-Inflammatory" Drugs and Their Effects on Type 2 Diabetes

2006 ◽  
Vol 8 (1) ◽  
pp. 18-27 ◽  
Author(s):  
Kevin A. Deans ◽  
Naveed Sattar
Keyword(s):  
Type 2 Diabetes ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Hydroxychloroquine: Looking into the Future

2017 ◽  
Vol 24 (4) ◽  
pp. 369-375 ◽  
Author(s):  
Saibal Chakravorty ◽  
Indranil Purkait ◽  
Anil Pareek ◽  
Avinash Talware
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Systemic Inflammation ◽  
Cardiovascular Effects ◽  
Lipid Lowering ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

AbstractHydroxychloroquine, an antimalarial agent has also been found to possess antidiabetic action. Onset of type-2 diabetes (T2DM) and cardiovascular disease is now considered to be the outcome of systemic inflammation. Many clinical trials are targeting systemic inflammation to reduce cardiovascular risk. Anti-inflammatory drugs with cardiovascular effects may be valuable therapeutic intervention to reduce massive cardiovascular risk in T2DM. In this review, antidiabetic action and potential cardioprotective role of hydroxychloroquine has been discussed. By virtue of its antidiabetic, lipid lowering, anti-platelet, anticoagulant and anti-inflammatory properties, hydroxychloroquine can be a key therapeutic alternative to manage patients with T2DM.

scholarly journals Anti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes

Molecules ◽  
2020 ◽  
Vol 25 (9) ◽  
pp. 2224 ◽  
Author(s):  
Alina Kuryłowicz ◽  
Krzysztof Koźniewski
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Low Grade ◽  
Peripheral Tissues ◽  
Inflammatory State ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Immunomodulatory Therapies

One of the concepts explaining the coincidence of obesity and type 2 diabetes (T2D) is the metaflammation theory. This chronic, low-grade inflammatory state originating from metabolic cells in response to excess nutrients, contributes to the development of T2D by increasing insulin resistance in peripheral tissues (mainly in the liver, muscles, and adipose tissue) and by targeting pancreatic islets and in this way impairing insulin secretion. Given the role of this not related to infection inflammation in the development of both: insulin resistance and insulitis, anti-inflammatory strategies could be helpful not only to control T2D symptoms but also to treat its causes. This review presents current concepts regarding the role of metaflammation in the development of T2D in obese individuals as well as data concerning possible application of different anti-inflammatory strategies (including lifestyle interventions, the extra-glycemic potential of classical antidiabetic compounds, nonsteroidal anti-inflammatory drugs, immunomodulatory therapies, and bariatric surgery) in the management of T2D.

Sign in / Sign up

Export Citation Format

Share Document